Catalys Pacific - About the company
Catalys Pacific is an unfunded company based in Cayman Islands, founded in 2019 by BT Slingsby and B T Slingsby. It operates as a Provider of diagnostic healthcare investment services. Catalys Pacific has not raised any funding yet. The company has 46 active competitors, including 6 funded and 9 that have exited. Its top competitors include companies like Orphalan, NIMBLE Diagnostics and Monarch Diagnostics.
Key Metrics
Founded Year
2019
Location
Stage
Unfunded
Ranked
1st among 46 active competitors
Employee Count
12 as on Jun 30, 2026
Investment & Acquisitions
Sign up to download Catalys Pacific's company profile
Catalys Pacific's funding and investors
Catalys Pacific has not raised any funding rounds yet.
Catalys Pacific's founders and board of directors
Founder? Claim ProfileThe founders of Catalys Pacific are BT Slingsby and B T Slingsby.
Here are the details of Catalys Pacific's key team members:
- BT Slingsby: Founder & Managing Partner of Catalys Pacific and founder of 1 other company.
- B T Slingsby: Founder of Catalys Pacific.
View details of Catalys Pacific's Founder profiles and Board Members
Catalys Pacific's employee count trend
Catalys Pacific has 12 employees as of Jun 26. Here is Catalys Pacific's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Catalys Pacific's Competitors and alternates
Top competitors of Catalys Pacific include Orphalan, NIMBLE Diagnostics and Monarch Diagnostics. Here is the list of Top 10 competitors of Catalys Pacific, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Catalys Pacific 2019, Cayman Islands, Unfunded | Provider of diagnostic healthcare investment services | - | - | 42/100 |
2nd | Developer and provider of access to innovative treatments to patients with rare diseases | - | 41/100 | ||
3rd | NIMBLE Diagnostics 2022, Badalona (Spain), Seed | Developer of diagnostic device for the detection of cardiovascular conditions | $1.08M | 35/100 | |
4th | Monarch Diagnostics 2019, Irvine (United States), Unfunded | Provider of diagnostic testing services | - | - | 35/100 |
5th | ![]() Shine Spect Janesville (United States), Unfunded | Provider of diagnostic radiopharmaceutical products and artificial intelligence solutions | - | - | 34/100 |
6th | Provider of home pathology sample collection and diagnostic tests services | $227K | 32/100 | ||
7th | Amber Pharmacy 2008, Singapore (Singapore), Acquired | Provider of customized approach to diagnosing and delivering specialty medications, with a patient-centric focus on convenient access, personalized care, and comprehensive support | - | - | 31/100 |
8th | Sequome 2022, United States, Series B | Provider of decodes and designs sequences to develop sequence medicines | $10.6M | - | 31/100 |
9th | Nutrasource 2002, Guelph (Canada), Acquired | Provider of marketing services for healthcare, nutraceutical & pharmaceutical sector | - | 31/100 | |
10th | PharmaReview 2011, London (United Kingdom), Late Stage | Provider of review pharmaceutical services for the lifesceince industry | - | 30/100 |
Looking for more details on Catalys Pacific's competitors? Click here to see the top ones
Catalys Pacific's Investments and acquisitions
Catalys Pacific has not made any acquisitions yet. Catalys Pacific has made 10 investments.Here is the list of latest three $investments:
Filter this list
Date of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Jul 22, 2026 | Investments | 2022 | San Diego (United States) | |
Sep 30, 2025 | Investments | 2022 | San Diego (United States) | |
Aug 20, 2024 | Investments | 2021 | Raleigh (United States) |
See all investments by Catalys Pacific
News related to Catalys Pacific
Media has covered Catalys Pacific for a total of 2 events in the last 1 year, 1 of them has been about company updates.
•
Novo-Backed Crystalys Debuts With $205M to Tackle GoutBioSpace•Sep 30, 2025•Crystalystx, AN Venture Partners, Catalys Pacific, KB Investment and 9 others
•
Pathalys secures $105m to advance SHPT drug through approvalPharmaceutical Technology•Aug 21, 2024•Pathalys, J P Morgan, Samsara BioCapital, Marshall Wace and 4 others
•
Pathalys raises $105M series B to prepare Japan-approved kidney disease drug for FDAFierce Biotech•Aug 20, 2024•Pathalys, TCG Crossover, J.P. Morgan Asset Management, Samsara BioCapital and 6 others
•
Pathalys Pharma Raises $105M in Series B FundingFinSMEs•Aug 20, 2024•Pathalys, TCG Crossover, J.P. Morgan Asset Management, Samsara BioCapital and 5 others
•
Renalys raises $37.8M to take Travere's kidney disease drug into Phase 3 trial in JapanEndPoints News•Jul 17, 2024•Renalys, Catalys Pacific, SR One, JP Investment and 1 other
•
Renalys’ ¥6B series A to fund phase III IgAN trial in JapanBioWorld•Jul 17, 2024•Renalys, Catalys Pacific, SR One, JP Investment and 1 other
•
Renalys Pharma to bring innovative medicines to Japan and other countries in AsiaBioSpectrum Asia•Jan 30, 2024•Catalys Pacific, SR One
•
•
Neuro Startup Arialys Raises $58M for Privilege of Tackling Brain InflammationMedCity News•Sep 13, 2023•Arialys, Avalon Bio Ventures, Astellas Pharma, Catalys Pacific and 2 others
•
Arialys Therapeutics Launches to Lead the Development of New Precision Medicines for Autoimmune Neuropsychiatric DiseasesBusiness Wire•Sep 12, 2023•Arialys, Avalon Bio Ventures, Catalys Pacific, MPM BioImpact and 2 others
Are you a Founder ?
FAQs about Catalys Pacific
Explore our recently published companies
- Capitalsfb.com - 2018 founded, Unfunded company
- Specule - Delhi based, 2017 founded, Unfunded company
- Tech Hive Technologies - Rawalpindi based, 2017 founded, Unfunded company
- Wise Accelerate - Hanoi based, 2021 founded, Unfunded company
- AblyCon Global - Bengaluru based, 2014 founded, Unfunded company
- Civoya - 2025 founded, Unfunded company
